Inactive Instrument

PCI Biotech Stock price Oslo Bors

Equities

Biotechnology & Medical Research

Sales 2021 6.27M 578K Sales 2022 4.75M 438K Capitalization 76.52M 7.05M
Net income 2021 -88M -8.11M Net income 2022 -55M -5.07M EV / Sales 2021 64.6 x
Net cash position 2021 114M 10.52M Net cash position 2022 55.83M 5.14M EV / Sales 2022 4.36 x
P/E ratio 2021
-5.87 x
P/E ratio 2022
-1.39 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 76.05%
More Fundamentals * Assessed data
Dynamic Chart
PCI Biotech Holding ASA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Pci Biotech Initiates Field Testing of Its Proprietary Technology for Gene Therapy Manufacturing CI
PCI Biotech Holding ASA Announces European Patent Office Intends to Grant A New Patent Covering Delivery of mRNA CI
PCI Biotech Holding ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
PCI Biotech Holding ASA Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
PCI Biotech Holding ASA Reports Earnings Results for the Full Year Ended December 31, 2022 CI
PCI Biotech Holding ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
PCI Biotech Holding ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
PCI Biotech Holding ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Transcript : PCI Biotech Holding ASA, Q2 2022 Earnings Call, Aug 31, 2022
PCI Biotech Announces PH II Clinical Trail Update CI
PCI Biotech Holding ASA Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Transcript : PCI Biotech Holding ASA, Q1 2022 Earnings Call, May 11, 2022
PCI Biotech CEO to Step Down to Join Exact Therapeutics MT
PCI Biotech Holding ASA Announces Resignation on Per Walday as Chief Executive Officer CI
More news
Managers TitleAgeSince
Chief Executive Officer 48 13-09-30
Chief Tech/Sci/R&D Officer 70 01-03-31
Corporate Officer/Principal 63 09-02-28
Members of the board TitleAgeSince
Chairman 69 15-05-16
Director/Board Member 75 16-04-30
Director/Board Member 65 19-04-30
More insiders
PCI Biotech Holding ASA is a cancer focused biopharmaceutical company based in Norway. The Company is developing therapeutic products based on its photochemical internalisation (PCI) technology. PCI Biotech's product is the photosensitiser fimaporfin (Amphinex). The PCI technology can enhance the effect of anticancer drugs by targeted, light-directed drug delivery into cancer cells, and can also be used as a platform that may both potentiate the effect of vaccines and enable macromolecules to reach intracellular targets. The PCI technology platform consists of two elements: a small molecule photosensitiser (named fimaporfin) and a light source. The primary aim of PCI is to introduce drug molecules or macromolecules into the cytosol of the target cells. It is this drug or macromolecule that gives the biological effect in a PCI treatment, and the intended biological effect may range from cell killing, through modification of gene expression to enhanced antigen presentation.
More about the company
  1. Stock
  2. Equities
  3. Stock PCI Biotech Holding ASA
  4. Stock PCI Biotech - Oslo Bors